9 news items
Wells Fargo Initiates Coverage On Amicus Therapeutics with Overweight Rating, Announces Price Target of $18
FOLD
30 May 24
Wells Fargo initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) with a Overweight rating and announces Price Target of $18.
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
FOLD
14 May 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
EIX
FOLD
FTRE
14 May 24
to Buy and increased the price target from $335 to $360. Boston Beer shares declined 2.5% to close at $283.82 on Monday
Guggenheim Upgrades Amicus Therapeutics to Buy, Announces $13 Price Target
FOLD
14 May 24
Guggenheim analyst Debjit Chattopadhyay upgrades Amicus Therapeutics (NASDAQ:FOLD) from Neutral to Buy and announces $13 price target.
UBS Maintains Buy on Amicus Therapeutics, Lowers Price Target to $19
FOLD
10 May 24
UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $20 to $19.
oh468qy6lttyo6qvwwegod7lspheb4de12m6pltk
FOLD
10 May 24
Morgan Stanley analyst Jeffrey Hung maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and lowers the price target from $20 to $19.
2xeengoflwen0zy4n2b5qe1uc1zp9t
FOLD
10 May 24
B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $14 to $13.
06pi60
BNTX
FOLD
GSK
26 Mar 24
(NASDAQ:BNTX), where the Group used its proprietary antibody discovery platforms to discover two undisclosed targets for BioNTech's preclinical
07ju9w10gt5iud2d0q6ldna
FOLD
18 Mar 24
JP Morgan analyst Anupam Rama maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and lowers the price target from $21 to $19.
- Prev
- 1
- Next